X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): SOTALOL HCI
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $69.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 26, 2020
Details:
This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
